CVS Health Corporation $CVS Shares Sold by Rothschild Investment LLC

Rothschild Investment LLC lowered its holdings in CVS Health Corporation (NYSE:CVS) by 5.0% in the second quarter, according to the company in its most recent disclosure with the SEC. The firm owned 56,259 shares of the pharmacy operator’s stock after selling 2,935 shares during the quarter. Rothschild Investment LLC’s holdings in CVS Health were worth $3,881,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also made changes to their positions in the stock. Cantor Fitzgerald Investment Advisors L.P. increased its stake in CVS Health by 1.6% in the 2nd quarter. Cantor Fitzgerald Investment Advisors L.P. now owns 409,735 shares of the pharmacy operator’s stock valued at $28,264,000 after purchasing an additional 6,615 shares in the last quarter. Brandywine Global Investment Management LLC boosted its position in CVS Health by 20.1% during the first quarter. Brandywine Global Investment Management LLC now owns 3,421,519 shares of the pharmacy operator’s stock worth $231,808,000 after purchasing an additional 572,533 shares in the last quarter. Skandinaviska Enskilda Banken AB publ grew its holdings in CVS Health by 122.5% in the first quarter. Skandinaviska Enskilda Banken AB publ now owns 565,152 shares of the pharmacy operator’s stock valued at $38,289,000 after purchasing an additional 311,098 shares during the last quarter. Universal Beteiligungs und Servicegesellschaft mbH increased its position in shares of CVS Health by 1.4% in the first quarter. Universal Beteiligungs und Servicegesellschaft mbH now owns 708,479 shares of the pharmacy operator’s stock valued at $47,999,000 after buying an additional 9,634 shares in the last quarter. Finally, Holderness Investments Co. acquired a new position in shares of CVS Health during the 1st quarter worth $300,000. 80.66% of the stock is owned by institutional investors and hedge funds.

CVS Health Stock Down 1.7%

CVS stock opened at $77.86 on Monday. The company has a 50 day moving average price of $77.70 and a two-hundred day moving average price of $69.96. The company has a debt-to-equity ratio of 0.83, a quick ratio of 0.62 and a current ratio of 0.83. The stock has a market capitalization of $98.84 billion, a P/E ratio of 204.90, a PEG ratio of 0.87 and a beta of 0.60. CVS Health Corporation has a one year low of $43.56 and a one year high of $85.15.

CVS Health (NYSE:CVS) last posted its quarterly earnings data on Wednesday, October 29th. The pharmacy operator reported $1.60 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.36 by $0.24. The business had revenue of $102.87 billion for the quarter, compared to analysts’ expectations of $98.85 billion. CVS Health had a return on equity of 11.45% and a net margin of 0.12%.The business’s revenue was up 7.8% on a year-over-year basis. During the same quarter last year, the firm earned $1.09 earnings per share. CVS Health has set its FY 2025 guidance at 6.550-6.650 EPS. As a group, sell-side analysts expect that CVS Health Corporation will post 5.89 EPS for the current year.

CVS Health Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Monday, November 3rd. Stockholders of record on Thursday, October 23rd were paid a dividend of $0.665 per share. The ex-dividend date of this dividend was Thursday, October 23rd. This represents a $2.66 dividend on an annualized basis and a dividend yield of 3.4%. CVS Health’s dividend payout ratio is currently 700.00%.

Wall Street Analyst Weigh In

Several equities analysts have weighed in on the stock. Jefferies Financial Group raised their target price on shares of CVS Health from $92.00 to $98.00 in a report on Thursday, October 30th. Morgan Stanley raised their price objective on shares of CVS Health from $82.00 to $89.00 and gave the stock an “overweight” rating in a research note on Tuesday, October 14th. Cantor Fitzgerald upped their target price on CVS Health from $78.00 to $95.00 and gave the company an “overweight” rating in a research note on Thursday, October 30th. Argus increased their target price on CVS Health from $80.00 to $91.00 and gave the company a “buy” rating in a report on Tuesday, November 4th. Finally, Mizuho boosted their price target on CVS Health from $76.00 to $88.00 and gave the stock an “outperform” rating in a report on Thursday, October 9th. Two investment analysts have rated the stock with a Strong Buy rating, twenty-one have assigned a Buy rating and four have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $89.41.

Insider Buying and Selling at CVS Health

In related news, Director Anne A. Finucane sold 7,500 shares of the firm’s stock in a transaction that occurred on Wednesday, August 20th. The shares were sold at an average price of $71.02, for a total value of $532,650.00. Following the sale, the director directly owned 22,156 shares of the company’s stock, valued at approximately $1,573,519.12. This trade represents a 25.29% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 1.22% of the stock is currently owned by insiders.

CVS Health Profile

CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services.